louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06370364: Nurses' Practice of Safe Blood Transfusion in Surgical and Critical Care Units
Official title: Contributing Factors Affecting Nurses' Practice of Safe Blood Transfusion in Surgical and Critical Care Units
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Practice Nurse's Scope
Blood Transfusion
Keywords: Nurses
Employment
Contributing factors
Practice
Blood
Transfusion
Lead sponsor: Matrouh University
Sponsor class: OTHER
First posted: 2024-04-17
Enrollment: 350
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: A convenience sampling was utilized to recruit 350 nurses from surgical and critical care units

Brief summary: Blood transfusions are an important part of nursing procedure. Nurses play a key role in safely administering blood products to patients in surgical and critical care unit

Detailed description: The aim of the study was to evaluate nurses' employment conditions as contributing factors affecting nurses' practice of safe blood transfusion in surgical and critical care units in Alexandria Main University Hospital.

Eligibility criteria: Inclusion Criteria:

Nurses

* willing to participate in the study
* work in surgical and critical care units
* Sign a consent

Exclusion Criteria:

* Nurses

  * Work in outpatient units and other units
  * Did not sign a consent

Primary outcomes:
measure: Questionnaire to measure factors affecting safe blood transfusion
timeFrame: one month
measure: observational checklist to measure nurses' practice of safe blood transfusion
timeFrame: three months
Secondary outcomes:
Other outcomes:
Locations:
city: Mersa Matruh
country: Egypt
facility: Faculty of Nursing, Matrouh University
Study officials:
affiliation: Faculty of Nursing, Matrouh University, Egypt
name: Nagah Abd El-Fattah Mohamed Aly, Ph.D
role: PRINCIPAL_INVESTIGATOR
affiliation: Faculty of Nursing, Matrouh University, Egypt
name: Wael M. Lotfy, Ph.D
role: STUDY_DIRECTOR
affiliation: Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Alexandria University, Egypt
name: Safaa M. El-Shanawany, Ph.D
role: STUDY_CHAIR
affiliation: Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Alexandria University, Egypt
name: Maha Ghanem, Ph.D
role: STUDY_CHAIR
affiliation: Faculty of Nursing, Matrouh University , Egypt
name: Hanaa Abbass, Ph.D
role: PRINCIPAL_INVESTIGATOR
affiliation: Faculty of Nursing, Matrouh University , Egypt
name: Maysa Elbiaa, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00572364: Open Label, Dose Escalation Phase I Study of AZD2281
Official title: A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of AZD2281 Following Single and Multiple Oral Doses in Patients in Japan With Advanced Solid Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Solid Malignancies
Keywords: Cancer
Advanced solid malignancies
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2007-12-13
Enrollment: 18
Sex: ALL
Minimum age (years): 20
Maximum age (years): 74
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to assess the safety and tolerability of AZD2281 following single and multiple oral doses in patients in Japan with advanced solid malignancies


Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed malignant solid tumour and refractory to standard therapy or for which no suitable effective standard therapy exists.

Exclusion Criteria:

* Patients undergone, within 4 weeks prior to trial entry, an anti-cancer therapy which includes chemotherapy (or a longer period depending on the defined characteristics of the drugs used eg,. 6 weeks for mitomycin C or nitrosourea.

Primary outcomes:
measure: The primary objective of this study is to determine the safety and tolerability of AZD2281.
timeFrame: assessed after each visit
Secondary outcomes:
measure: The secondary objectives of the study are to determine MTD and pharmacokinetic profile of oral AZD2281.
timeFrame: assessed after each visit
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Research Site
Study officials:
affiliation: KuDOS/AstraZeneca
name: James Carmichael
role: STUDY_DIRECTOR
References:
citation: Yamamoto N, Nokihara H, Yamada Y, Goto Y, Tanioka M, Shibata T, Yamada K, Asahina H, Kawata T, Shi X, Tamura T. A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors. Cancer Sci. 2012 Mar;103(3):504-9. doi: 10.1111/j.1349-7006.2011.02179.x. Epub 2012 Jan 30.
Clinical trial NCT04337164: Radiological Study of PENG Block Depth
Official title: Observational Tomodensitometric Study of the Anatomical Landmarks Depth Required to Perform Femoral Nerve Block or PENG Block. The Tomo-PENG Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Regional Anesthesia
Computed Tomography
Anatomical Description
Keywords: PENG block
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2020-04-07
Enrollment: 101
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who had a CT scan in a single institution

Brief summary: This study evaluates the depth of anatomical landmarks required in regional anaesthesia to perform either Femoral Nerve Block or PENG Block.

Measures will be performed on abdominal and pelvic computed tomography as part of daily routine patient care.

Detailed description: PENG Block is a new approach in regional anesthesia for hip surgery. The anatomical landmarks used to perform PENG Block are deeper than those for Femoral Nerve Block. Nevertheless, depth required for PENG Block is not yet evaluated since it may vary between patients.

Daily routine abdominal and pelvic computed tomography allow such anatomical description.

Eligibility criteria: Inclusion Criteria:

* All adult patients who have had a CT scan including visualization of the pelvis and who have expressed no opposition

Exclusion Criteria:

* pregnancy
* Subject presenting a pathology likely to modify the anatomical landmarks studied: ie pelvic fracture, psoas haematoma, previous pelvic surgery or hip prosthesis or femoral bypass

Primary outcomes:
measure: PENG Block depth
timeFrame: 1 hour after radiological examination
Secondary outcomes:
measure: Femoral Nerve Block depth
timeFrame: 1 hour after radiological examination
measure: puncture angle needed
timeFrame: 1 hour after radiological examination
measure: needle length needed
timeFrame: 1 hour after radiological examination
Other outcomes:
Locations:
city: Besançon
country: France
facility: Centre Hospitalier Universitaire
Study officials:
References:
Clinical trial NCT01271764: The Association of G9a Protein and Outcome of Patients With Endometrial Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Outcome of Endometrial Cancer
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2011-01-07
Enrollment: 97
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Tumor invasion and metastasis are the major causes of cancer-related death. Some studies have found that histone methyltransferases, such as EZH2, specifically affect metastasis in breast, gastric and prostate cancer. The functional roles of other members of the HMT family such as G9a in cancer remain obscure. Therefore, the investigators will investigate whether G9a have a role in recurrence/metastasis of endometrial cancer.


Eligibility criteria: Inclusion Criteria:

* all cases with endometrial cancer underwent staging operation

Exclusion Criteria:

* nil

Primary outcomes:
measure: The role of G9a protein in endometrial cancer
timeFrame: overall survial, disease-free survival
Secondary outcomes:
Other outcomes:
Locations:
city: Banqiao
country: Taiwan
facility: Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital
state: New Taipei
Study officials:
References:
Clinical trial NCT03832764: Non-invasive Pain Monitoring in Post-operative Patients
Official title: Observational Study for the Evaluation of a New Non-invasive Painmonitor Used in Clinic in Awakening, Postoperative Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pain, Postoperative
Keywords: skin impedance
pain monitoring
observational study
PACU/ICU
Lead sponsor: University Ghent
Sponsor class: OTHER
Collaborators: name: University Hospital, Ghent
First posted: 2019-02-06
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients planned for operation, between 18 and 70 years old, not pregnant, not in chronic pain and not taken anticonvulsants or antidepressants.

Brief summary: During the current pain monitoring system the patient is awake and he/she is asked to give a numerical scale rating from 0 (no pain) to 10 (extreme pain). The purpose is to correlate the non-invasive measurements of the prototype device ANSPEC-PRO with these numbers to develop later a method/algorithm for automatic evaluation of pain (objective measurement of pain). The measurement is done using standard ECG electrodes placed in the hand palm of the patient. The patient feels nothing during the observations, perhaps irritation of skin may occur as result of long time measurement. As a comparison to the investigators prototype, a commercial device is also used in (randomly selected) patients, i.e. the MedStorm device.

The study will try to answer the following questions:

* Are the measurements with the ANSPEC-PRO correlated with the NRS values?
* What is the (mathematical) relationship between the measured values and the NRS?
* Is there difference between the two devices in measuring pain levels? And what is this difference if pain alleviation medication is given to the patient?
* A number of 26 patients is envisaged for this study, equally distributed to be evaluated with the two devices.


Eligibility criteria: Inclusion Criteria:

* patients postoperative of a painfull operation
* between 18 and70 years old

Exclusion Criteria:

* day surgery patients
* chronic pain patients
* taken medication : anticonvulsants

Primary outcomes:
measure: Evaluation of a new non-invasive painmonitor used in clinic awakening, postoperative patients.
timeFrame: 140 minutes each patient
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: Clara Ionescu
state: Oost-Vlaanderen
Study officials:
References:
Clinical trial NCT06428864: Effect of the Use of a 3D Scanner Application on a Smartphone to Mold Garchois Orthotic Device in Neuromuscular Diseases Patients With Scoliosis
Official title: Effect of the Use of a 3D Scanner Application on a Smartphone to Mold Garchois Orthotic Device in Neuromuscular Diseases Patients With Scoliosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neuromuscular Diseases
Scoliosis
Keywords: Scoliosis
Neuromuscular Diseases
Orthotic device
Brace
Cast
3D Scan application
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2024-05-24
Enrollment: 40
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Neuromuscular patients from a paediatric rehabilitation center

Brief summary: Neuromuscular scoliosis is the consequence of general hypotonia involved in certain neuromuscular diseases. Thoracic braces are necessary to slow down the deformation. In France, Garchois brace is largely used in this context because of a better pulmonary tolerance.

Historically, molding of thoracic orthotic brace was based on a plaster cast directly on the patient. He/she is suspended in a frame or is lying on an examining table, and is held by 4 therapists (a physician, an orthoprosthesist, a nurse and a doctor). The position during molding could be very uncomfortable and anxious.

With the development of new technologies, a 3D scan application on smartphone to obtain the volume and deformations of the patient was developed. This tool enables digital acquisition of trunk and head volume while bypassing the seated patient. No plaster strips are used. The resulting negative is digitally filled to obtain a positive. The positive is then corrected before the corset is made, either digitally or after 3D scanning, in plaster or foam. This application was first used in our department in 2017.

The aim of this retrospective monocentric study is to show that this application can be used to produce brace that are as corrective and reliable as braces made after plaster casting, while improving the satisfaction of children, their families and professionals during impression taking. as their parents and of the professionals present during the molding.


Eligibility criteria: Inclusion Criteria:

* Clinical suspicion or genetically confirmed neuromuscular disease
* Neuromuscular scoliosis, with Garchois brace indication
* Under 18 at the time of the first Garchois brace molding

Exclusion Criteria:

* Other neuro-orthopaedic disease such as cerebral palsy
* Other thoracic brace than Garchois
* Any spine surgery

Primary outcomes:
measure: Assessment of Cobb angles
timeFrame: Up to 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Bron
country: France
facility: L'Escale - HFME
Study officials:
References:
Clinical trial NCT00785564: Imaging Cardiac Electrical Remodeling With Electrocardiogram Imaging (ECGI)
Official title: Imaging Cardiac Electrical Remodeling With ECGI
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sick Sinus Syndrome
Keywords: T-wave memory
Sick Sinus Syndrome
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2008-11-05
Enrollment: 13
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients of a pacemaker clinic

Brief summary: A consequence of chronic RV pacing is a process of electrical remodeling that alters myocardial repolarization to reflect the altered depolarization induced by the RV lead. When RV pacing is discontinued, the altered repolarization persists for several weeks. This phenomena is traditionally described as "T-wave memory" based upon the 12-lead ECG appearance of inverted T-Waves. The investigators are using the ECGI technique to produce three dimensional electroanatomical images of this phenomena in patients with dual chamber pacemakers. Echocardiography will also be used to image the mechanical effects of RV pacing and T-wave memory. The images will show the spatial distribution of altered repolarization and allow us to correlate any mechanical consequences of this phenomena that may exist.


Eligibility criteria: Inclusion Criteria:

* Implanted dual chamber pacemaker for sick sinus syndrome with no history of complete heart block.

Exclusion Criteria:

* Persistent atrial fibrillation that is not suppressed by medications.

Primary outcomes:
measure: ECGI Image
timeFrame: 1 month after RV pacing
Secondary outcomes:
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Mitchell N Faddis, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00186264: Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?
Official title: Does Concurrent Hydrocortisone With Venlafaxine XR Speed Antidepressant Response?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Depressive Disorder, Major
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: Wyeth is now a wholly owned subsidiary of Pfizer
First posted: 2005-09-16
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to examine whether IV hydrocortisone can speed up the time required for Venlafaxine XR to work.

Detailed description: Participants will be treated with Venlafaxine XR for 6 weeks. The dose of Venlafaxine XR will begin at 37.5 mg/day and be gradually increased to a maximum of 225 mg/day. The dose may be kept as low as 75 mg/day if necessary. Study doctor will be assessing mood to determine if some patients respond more quickly than the several weeks often required for an antidepressant to begin working. On the first day of treatment with Venlafaxine XR, participant will be randomly assigned (similar to a flip of a coin) to receive hydrocortisone 15 mg /day or placebo for two days. Placebo is an inactive substance, like a sugar pill. This dose of hydrocortisone is less than a typical replacement dose for patients who are not producing cortisol (hydrocortisone) naturally. The hydrocortisone is administered intravenously (in a vein) over the course of 2 hours for two consecutive days. Neither participant nor study doctor will know which treatment participant is receiving. However, this information is available to study doctor if it is needed.

Eligibility criteria: Inclusion Criteria::- outpatients at least 18 years of age

* current major depressive episode
* HDRS greater than or equal to 21
* good physical health Exclusion Criteria:- history of sensitivity, intolerance, or non-response to venlafaxine
* history of sensitivity to hydrocortisone
* history of bipolar 1 illness
* meets DSM-IV criteria for a current or past psychotic disorder
* meets DSM-IV criteria for substance abuse or dependence in previous 6 months
* significant imminent suicide risk
* medical condition that would compromise participation in the study
* woman of child bearing potential not using adequate birth control in the opinion of the investigator

Primary outcomes:
measure: To determine if treatment of major depression with hydrocortisone concurrent with starting venlafaxine XR speeds onset of antidepressant action.
Secondary outcomes:
measure: To determine if hydrocortisone pre-treatment augments venlafaxine XR response.
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Charles DeBattista
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04498364: Extinction Learning in Adults With Tourette Syndrome
Official title: Extinction Learning in Adults With Tourette Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tourette Syndrome
Habit Reversal Training
Tic Disorders
Tics
Comprehensive Behavioral Intervention for Tics
Keywords: Extinction Learning
Comprehensive Behavioral Intervention for Tics
Behavior Therapy
Habit Reversal Training
Tourette's Disorder
Lead sponsor: Johns Hopkins University
Sponsor class: OTHER
First posted: 2020-08-04
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Aversive sensory phenomena such as premonitory urges play a central role in the behavioral treatment model of tics. Extinction learning and extinction recall are learning processes implicated within this model, but are still understudied for individuals with Tourette syndrome (TS). This study examines extinction learning and extinction recall in adults with TS using an experimental task. This study will also explore the relationship between extinction processes (i.e., extinction learning and extinction recall) and treatment outcomes with behavior therapy. Findings from this investigation will be used to update the behavioral treatment model, which serves as the basis for evidence-based behavioral interventions.


Eligibility criteria: Inclusion Criteria:

* At least 18 years old,
* Have moderate tic severity or greater as evidenced by a YGTSS Total Tic Score greater than 13 (\>9 for youth with motor or vocal tics only)
* Have not received more than 4 previous sessions of HRT
* Be fluent in English
* Medication free or on a stable dose of psychiatric medication for 8 weeks prior to enrollment.

Exclusion Criteria:

* An inability to complete rating scales
* An inability to attend study visits

Primary outcomes:
measure: Tic severity as assessed by the Hopkins Motor and Vocal Tic Scale (HM/VTS)
timeFrame: Within 1 week after completion of HRT
Secondary outcomes:
measure: Tic severity as assessed by the Yale Global Tic Severity Scale-Revised (YGTSS)
timeFrame: Within 1 week after completion of HRT
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Johns Hopkins University School of Medicine
state: Maryland
Study officials:
affiliation: Johns Hopkins University
name: Joseph F McGuire, PhD
role: PRINCIPAL_INVESTIGATOR
References: